Table 4.
Table to show sequential gain in autoantibodies, and those associated with clinical change.
| First Ab | Second Ab | Third Ab | Significant change in clinical phenotype |
|---|---|---|---|
| ATA | U1RNP | Panniculitis | |
| ACA | U1RNP | No | |
| U1RNP | ARA | Developed dcSSc from lcSSc | |
| ACA | PmScl | No | |
| U3RNP | ACA | No | |
| U1RNP | ARA | No | |
| U1RNP | U3RNP | Myositis | |
| U3RNP | ACA | No | |
| ATA | U1RNP | ACA | With U1RNP developed ILD, and dcSSc. With ACA- new onset severe DUs |
| PmScl | ACA | No | |
| ATA | U1RNP | ILD | |
| ATA | Ku | No | |
| Ku | ATA | PAH | |
| ATA | ACA | No | |
| ATA | U1RNP | No | |
| U3RNP, U1RNP | Ku | Myositis, cardiac | |
| ATA | Ku | No |
DUs, digital ulcers; ILD, interstitial lung disease; dcSSc, diffuse cutaneous systemic sclerosis; lcSSc, limited cutaneous systemic sclerosis.